نتایج جستجو برای: ifn therapy

تعداد نتایج: 685719  

2011
Anna Kreutzman Peter Rohon Edgar Faber Karel Indrak Vesa Juvonen Veli Kairisto Jaroslava Voglová Marjatta Sinisalo Emília Flochová Jukka Vakkila Petteri Arstila Kimmo Porkka Satu Mustjoki

Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-α treated patients were able to discontinue therapy without disease progression. The aim of this project was to study the immunomodulatory effects of IFN-α in CML patients in prolonged remission and isolate biological markers predicting...

Journal: :hepatitis monthly 0
alireza mehrazmay baqiyatallah research center for gastroenterology and liver disease, baqiyatallah hospital, tehran, ir iran seyed moayed alavian baqiyatallah research center for gastroenterology and liver disease, baqiyatallah hospital, tehran, ir iran; baqiyatallah research center for gastroenterology and liver disease, baqiyatallah hospital, tehran, ir iran. tel: +98-2188067114, fax: +98-2188067114 maziar moradi-lakeh department of community medicine, school of medicine, gastrointestinal and liver disease research center (gildrc), iran university of medical science, tehran, ir iran mahdi mokhtari payam department of community medicine, school of medicine, gastrointestinal and liver disease research center (gildrc), iran university of medical science, tehran, ir iran amir hashemi-meshkini department of pharmacoeconomics and pharmaceutical administration, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran; non-communicable disease research center, endocrinology and metabolism research institute, tehran university of medical sciences, tehran, ir iran bita behnava baqiyatallah research center for gastroenterology and liver disease, baqiyatallah hospital, tehran, ir iran

conclusions adding low dose of ribavirin to peg ifn alfa-2a for treatment of chronic hepatitis c patients with genotype-1 was “highly cost effective” and in patients with low viral load and in previous monotherapy resistant patients was “cost effective.” results the incremental cost effectiveness ratio (icer) for combination therapy in genotype-1 and genotypes non-1 subgroups was 2,673 and 19,2...

2017
Hang Yin Cheng-Gong Liao Jian-Guo Huang Yong-Qiang Wang Zheng Li Lu-Lu Fan Men-Long Qian Nao Wan Ning Lu

The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The rema...

2007
Nyingi Kemmer Guy W Neff

Patients with chronic hepatitis C virus (HCV) infection and disease-related complications - among them cirrhosis and liver failure - pose a particular management challenge. Some of these patients may fail to respond to current therapy (non-responders), and some are affected so severely that treatment puts them at an unacceptable risk for complications. Treatment with pegylated interferon (peg-I...

Journal: :Journal of virology 2016
Kerry J Lavender Kathrin Gibbert Karin E Peterson Erik Van Dis Sandra Francois Tyson Woods Ronald J Messer Ali Gawanbacht Janis A Müller Jan Münch Katie Phillips Brent Race Michael S Harper Kejun Guo Eric J Lee Mirko Trilling Hartmut Hengel Jacob Piehler Jens Verheyen Cara C Wilson Mario L Santiago Kim J Hasenkrug Ulf Dittmer

UNLABELLED Although all 12 subtypes of human interferon alpha (IFN-α) bind the same receptor, recent results have demonstrated that they elicit unique host responses and display distinct efficacies in the control of different viral infections. The IFN-α2 subtype is currently in HIV-1 clinical trials, but it has not consistently reduced viral loads in HIV-1 patients and is not the most effective...

2016
Ahmed Lasfar Andrew de la Torre Walid Abushahba Karine A Cohen-Solal Ismael Castaneda Yao Yuan Kenneth Reuhl Andrew Zloza Elizabeth Raveche Debra L Laskin Sergei V Kotenko

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-λ, a new type of IFN that acts through its own ...

Journal: :Chang Gung medical journal 2007
Yung Che Chen Sheng-Nan Lu Meng-Chih Lin

Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Then the patient began to complain of dyspnea on exertion and a dry c...

Journal: :cell journal 0

objective: multiple sclerosis (ms) is one of the leading neurodegenerative causes of physical disability world-wide. genetic aberrations of autoimmunity pathway components have been demonstrated to significantly influence ms development. cluster of differentiation 58 (cd58) is pertained to a group of genes which had been assayed in several recent association studies. given the significance of c...

2012
Hideto Nakajima Takafumi Hosokawa Yoshimitu Doi Toshiyuki Ikemoto Shimon Ishida Fumiharu Kimura Toshiaki Hanafusa

A Japanese randomized controlled study showed that Interferon â (IFN-â1b) therapy is clinically effective in decreasing the frequency of attacks in multiple sclerosis (MS), even in optico-spinal MS (OSMS). However, recent studies have shown that IFN-â (IFN-â1a/IFN-â1b) treatment was not effective in neuromyelitis optica (NMO) patients and that the diminished benefit of IFN-â treatment in NMO m...

Journal: :Journal of virology 2000
J Nousbaum S J Polyak S C Ray D G Sullivan A M Larson R L Carithers D R Gretch

The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein has been controversially implicated in the inherent resistance of HCV to interferon (IFN) antiviral therapy in clinical studies. In this study, the relationship between NS5A mutations and selection pressures before and during antiviral therapy and virologic response to therapy were investigated. Full-length NS5A clones were sequenced f...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید